- In November 2021, Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, announced that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) to treat spinocerebellar ataxia (SCA). Additionally, the FDA granted the program Fast Track designation for SCA in the U.S. SLS-005 has also received Orphan Drug designation for spinocerebellar ataxia type 3 (SCA3) from both the FDA and the European Medicines Agency (EMA) in the EU
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (MJD Type I, MJD Type II, and MJD Type III), Drugs Type (L- dopa, Baclofen, and Botulinum Toxin), Route of Administration (Oral, Parenteral, and Others), End-Users (Clinics, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2032
.
The Global Machado Joseph Disease Treatment Market size was valued at USD 350.41 USD Million in 2024.
The Global Machado Joseph Disease Treatment Market is projected to grow at a CAGR of 4.77% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
